Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B1 | P14061 | 18/20 | 0.44 |
| ▸ | HSD17B2 | P37059 | 18/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | STS | P08842 | 1/20 | 0.38 |
| ▸ | CES2 | O00748 | 1/20 | 0.38 |
| ▸ | CES1 | P23141 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7146004 | 0.84 | CES2 (0.46) | CES2CES1 | |
| SCHEMBL29782972 | 0.84 | CES2 (0.46) | CES2CES1 | |
| SCHEMBL27433691 | 0.80 | HSD17B1 (0.49) | HSD17B1HSD17B2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL31197230 | 0.80 | HSD17B1 (0.49) | HSD17B1HSD17B2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL201397 | 0.79 | HSD17B1 (0.41) | HSD17B1HSD17B2CYP3A4STSCES2 | |
| SCHEMBL202186 | 0.79 | HSD17B1 (0.46) | HSD17B1HSD17B2CYP3A4 | |
| SCHEMBL24445882 | 0.78 | THRB (0.46) | HSD17B1HSD17B2CYP3A4 | |
| SCHEMBL17275022 | 0.78 | CES2 (0.38) | CYP3A4CYP2C9CYP2C19CES2CES1 | |
| SCHEMBL6818860 | 0.78 | PBRM1 (0.41) | CES2CES1 | |
| SCHEMBL30739599 | 0.78 | CES2 (0.38) | CYP3A4CYP2C9CYP2C19CES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 102 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111848540-A | Chain transfer agent for preparing antibacterial polymer and preparation method thereof | 吴张峰 | 2020-10-30 | — | — | CN | claimed |
| CN-111728837-A | Exercise massage belt capable of rubbing abdomen and chest and throwing butterfly sleeves and preparation method thereof | 万贤能 | 2020-10-02 | — | — | CN | claimed |
| US-20250257074-A1 | SYNTHETIC PROCESSES AND SYNTHETIC INTERMEDIATES | TAXIS PHARMACEUTICALS, INC. (US) | 2025-08-14 | — | — | US | disclosed |
| US-20250206755-A1 | ANTIMICROBIAL AGENTS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2025-06-26 | — | — | US | disclosed |
| US-20250179008-A1 | ANTIBACTERIAL AGENTS | TAXIS PHARMACEUTICALS, INC. (US) | 2025-06-05 | — | — | US | disclosed |
| US-12173013-B2 | Synthetic processes and synthetic intermediates | TAXIS PHARMACEUTICALS, INC. (US) | 2024-12-24 | — | — | US | disclosed |
| US-12061201-B2 | Fluorescent probes for the visualization of FtsZ in gram-positive and gram-negative bacterial pathogens | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2024-08-13 | — | — | US | disclosed |
| CN-110891566-B | Synthesis method and synthesis intermediate | 塔克西斯医药股份有限公司 | 2023-12-19 | — | — | CN | disclosed |
| US-20230257397-A1 | SYNTHETIC PROCESSES AND SYNTHETIC INTERMEDIATES | TAXIS PHARMACEUTICALS, INC. (US) | 2023-08-17 | — | — | US | disclosed |
| US-20230257397-A1 | SYNTHETIC PROCESSES AND SYNTHETIC INTERMEDIATES | TAXIS PHARMACEUTICALS, INC. (US) | 2023-08-17 | — | — | US | disclosed |
| US-20230257397-A1 | SYNTHETIC PROCESSES AND SYNTHETIC INTERMEDIATES | TAXIS PHARMACEUTICALS, INC. (US) | 2023-08-17 | — | — | US | disclosed |
| US-20100173933-A1 | ANTIBACTERIAL AGENTS | PROLYSIS LTD (GB) | 2010-07-08 | — | — | US | disclosed |
| US-20100173933-A1 | ANTIBACTERIAL AGENTS | PROLYSIS LTD (GB) | 2010-07-08 | — | — | US | disclosed |
| EP-2203219-A1 | SUBSTITUTED BENAMIDINES AS ANTIBACTERIAL AGENTS | Biota Europe Ltd (GB) | 2010-07-07 | — | — | EP | disclosed |
| EP-2200991-A1 | ANTIBACTERIAL AGENTS | Biota Europe Ltd (GB) | 2010-06-30 | — | — | EP | disclosed |
| WO-2009040507-A1 | SUBSTITUTED BENAMIDINES AS ANTIBACTERIAL AGENTS | PROLYSIS LTD (GB) | 2009-04-02 | — | — | WO | disclosed |
| WO-2009037485-A1 | ANTIBACTERIAL AGENTS | PROLYSIS LTD (GB) | 2009-03-26 | — | — | WO | disclosed |
| EP-1996180-A1 | ANTIBACTERIAL AGENTS | Prolysis Limited (GB) | 2008-12-03 | — | — | EP | disclosed |
| WO-2007107758-A1 | ANTIBACTERIAL AGENTS | PROLYSIS LTD (GB) | 2007-09-27 | — | — | WO | disclosed |
| WO-2007107758-A1 | ANTIBACTERIAL AGENTS | PROLYSIS LTD (GB) | 2007-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230257397-A1 | SYNTHETIC PROCESSES AND SYNTHETIC INTERMEDIATES | TXN, TBXAS1, TXK | HSD17B1 3460/4885HSD17B2 3824/4885CYP3A4 367/4885 |
| US-12061201-B2 | Fluorescent probes for the visualization of FtsZ in gram-positive and gram-negative bacterial pathogens | CDC42, DNM1L, IK | HSD17B1 3180/4885HSD17B2 3655/4885CYP3A4 4764/4885 |
| US-20250257074-A1 | SYNTHETIC PROCESSES AND SYNTHETIC INTERMEDIATES | TXN, TBXAS1, TXK | HSD17B1 3460/4885HSD17B2 3824/4885CYP3A4 367/4885 |
| US-20250206755-A1 | ANTIMICROBIAL AGENTS | CFTR, MRPL21, ARG1 | HSD17B1 3123/4885HSD17B2 3540/4885CYP3A4 1709/4885 |
| US-20250179008-A1 | ANTIBACTERIAL AGENTS | ALK, ROS1, NOX1 | HSD17B1 2303/4885HSD17B2 2276/4885CYP3A4 795/4885 |
| US-20100173933-A1 | ANTIBACTERIAL AGENTS | ALK, ROS1, NOX1 | HSD17B1 2303/4885HSD17B2 2276/4885CYP3A4 795/4885 |
| US-12173013-B2 | Synthetic processes and synthetic intermediates | TXN, TBXAS1, TXK | HSD17B1 3460/4885HSD17B2 3824/4885CYP3A4 367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.